Cervical Dystonia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cervical Dystonia Market Outlook

Thelansis’s “Cervical Dystonia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cervical Dystonia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cervical Dystonia Overview

Cervical dystonia, alternatively termed spasmodic torticollis, is an uncommon neurological condition stemming from a brain malfunction. It stands as the most prevalent form of focal dystonia. Characterized by involuntary muscle contractions in the neck, cervical dystonia leads to abnormal movements and positions of the neck and head. Patients with CD are typically categorized into two groups: primary CD, which is idiopathic, and secondary CD, which arises due to identifiable causes. Primary CD lacks evidence from history, physical examination, or laboratory tests (except for the primary dystonia gene), pointing to any secondary cause for the dystonic symptoms. It can be a generalized or focal dystonic condition component, with a possible genetic basis in generalized cases. Secondary or symptomatic CD may result from central or peripheral trauma, exposure to dopamine receptor antagonists (tardive), neurodegenerative disease, or other conditions linked to abnormal basal ganglia function. Most isolated cases of cervical dystonia are idiopathic, although a genetic predisposition may be present, as suggested by a positive family history in roughly 10-25 percent of cases. Cervical dystonia has been associated with genetic mutations in several genes (GNAL, THAP1, CIZ1, and ANO3) and environmental factors. FDA-approved drugs for treating Cervical dystonia include Daxxify (daxibotulinumtoxinA-lanm) for injection, Xeomin (incobotulinumtoxinA), and Myobloc (rimabotulinumtoxinB).

• The incidence of diagnosed cases of Cervical dystonia/Spasmodic torticollis ranges from 22 to 31 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: